vs
EXACT SCIENCES CORP（EXAS）与思佳讯（SWKS）财务数据对比。点击上方公司名可切换其他公司
思佳讯的季度营收约是EXACT SCIENCES CORP的1.2倍（$1.0B vs $878.4M），思佳讯净利率更高（7.6% vs -9.8%，领先17.4%），EXACT SCIENCES CORP同比增速更快（23.1% vs 8.6%），思佳讯自由现金流更多（$339.0M vs $120.4M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -0.5%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
思佳讯是总部位于美国加利福尼亚州尔湾的半导体企业，公司股票在纳斯达克全球精选市场挂牌交易，股票代码为SWKS，同时也是标普500指数的成分股之一，在全球射频半导体领域拥有较高市场地位。
EXAS vs SWKS — 直观对比
营收规模更大
SWKS
是对方的1.2倍
$878.4M
营收增速更快
EXAS
高出14.5%
8.6%
净利率更高
SWKS
高出17.4%
-9.8%
自由现金流更多
SWKS
多$218.6M
$120.4M
两年增速更快
EXAS
近两年复合增速
-0.5%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.0B |
| 净利润 | $-86.0M | $79.2M |
| 毛利率 | 70.1% | 41.3% |
| 营业利润率 | -9.4% | 10.0% |
| 净利率 | -9.8% | 7.6% |
| 营收同比 | 23.1% | 8.6% |
| 净利润同比 | 90.1% | 15.3% |
| 每股收益（稀释后） | $-0.45 | $0.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASSWKS
| Q1 26 | — | $1.0B | ||
| Q4 25 | $878.4M | $1.1B | ||
| Q3 25 | $850.7M | — | ||
| Q2 25 | $811.1M | $965.0M | ||
| Q1 25 | $706.8M | $953.2M | ||
| Q4 24 | $713.4M | $1.1B | ||
| Q3 24 | $708.7M | $1.0B | ||
| Q2 24 | $699.3M | $905.5M |
净利润EXASSWKS
| Q1 26 | — | $79.2M | ||
| Q4 25 | $-86.0M | $141.4M | ||
| Q3 25 | $-19.6M | — | ||
| Q2 25 | $-1.2M | $105.0M | ||
| Q1 25 | $-101.2M | $68.7M | ||
| Q4 24 | $-864.6M | $162.0M | ||
| Q3 24 | $-38.2M | $60.5M | ||
| Q2 24 | $-15.8M | $120.9M |
毛利率EXASSWKS
| Q1 26 | — | 41.3% | ||
| Q4 25 | 70.1% | 40.7% | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | 41.6% | ||
| Q1 25 | 70.8% | 41.1% | ||
| Q4 24 | 69.0% | 41.4% | ||
| Q3 24 | 69.4% | 41.9% | ||
| Q2 24 | 69.8% | 40.2% |
营业利润率EXASSWKS
| Q1 26 | — | 10.0% | ||
| Q4 25 | -9.4% | 10.1% | ||
| Q3 25 | -3.0% | — | ||
| Q2 25 | -0.3% | 11.5% | ||
| Q1 25 | -13.6% | 10.2% | ||
| Q4 24 | -122.8% | 16.9% | ||
| Q3 24 | -5.6% | 5.8% | ||
| Q2 24 | -3.8% | 14.4% |
净利率EXASSWKS
| Q1 26 | — | 7.6% | ||
| Q4 25 | -9.8% | 12.9% | ||
| Q3 25 | -2.3% | — | ||
| Q2 25 | -0.1% | 10.9% | ||
| Q1 25 | -14.3% | 7.2% | ||
| Q4 24 | -121.2% | 15.2% | ||
| Q3 24 | -5.4% | 5.9% | ||
| Q2 24 | -2.3% | 13.4% |
每股收益（稀释后）EXASSWKS
| Q1 26 | — | $0.53 | ||
| Q4 25 | $-0.45 | $0.95 | ||
| Q3 25 | $-0.10 | — | ||
| Q2 25 | $-0.01 | $0.70 | ||
| Q1 25 | $-0.54 | $0.43 | ||
| Q4 24 | $-4.69 | $1.00 | ||
| Q3 24 | $-0.21 | $0.36 | ||
| Q2 24 | $-0.09 | $0.75 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $1.6B |
| 总债务越低越好 | — | $496.6M |
| 股东权益账面价值 | $2.4B | $5.8B |
| 总资产 | $5.9B | $7.9B |
| 负债/权益比越低杠杆越低 | — | 0.09× |
8季度趋势，按日历期对齐
现金及短期投资EXASSWKS
| Q1 26 | — | $1.6B | ||
| Q4 25 | $964.7M | $1.4B | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $858.4M | $1.3B | ||
| Q1 25 | $786.2M | $1.5B | ||
| Q4 24 | $1.0B | $1.7B | ||
| Q3 24 | $1.0B | $1.6B | ||
| Q2 24 | $946.8M | $1.3B |
总债务EXASSWKS
| Q1 26 | — | $496.6M | ||
| Q4 25 | — | $496.4M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $496.2M | ||
| Q1 25 | — | $995.1M | ||
| Q4 24 | — | $994.7M | ||
| Q3 24 | — | $994.3M | ||
| Q2 24 | — | $994.0M |
股东权益EXASSWKS
| Q1 26 | — | $5.8B | ||
| Q4 25 | $2.4B | $5.8B | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | $5.7B | ||
| Q1 25 | $2.4B | $5.9B | ||
| Q4 24 | $2.4B | $6.4B | ||
| Q3 24 | $3.2B | $6.3B | ||
| Q2 24 | $3.2B | $6.3B |
总资产EXASSWKS
| Q1 26 | — | $7.9B | ||
| Q4 25 | $5.9B | $7.9B | ||
| Q3 25 | $5.9B | — | ||
| Q2 25 | $5.8B | $7.7B | ||
| Q1 25 | $5.7B | $7.9B | ||
| Q4 24 | $5.9B | $8.3B | ||
| Q3 24 | $6.7B | $8.3B | ||
| Q2 24 | $6.7B | $8.2B |
负债/权益比EXASSWKS
| Q1 26 | — | 0.09× | ||
| Q4 25 | — | 0.09× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.09× | ||
| Q1 25 | — | 0.17× | ||
| Q4 24 | — | 0.16× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $395.5M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $339.0M |
| 自由现金流率自由现金流/营收 | 13.7% | 32.7% |
| 资本支出强度资本支出/营收 | 3.6% | 5.5% |
| 现金转化率经营现金流/净利润 | — | 4.99× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $1.1B |
8季度趋势，按日历期对齐
经营现金流EXASSWKS
| Q1 26 | — | $395.5M | ||
| Q4 25 | $151.7M | $200.0M | ||
| Q3 25 | $219.9M | — | ||
| Q2 25 | $89.0M | $314.2M | ||
| Q1 25 | $30.8M | $409.4M | ||
| Q4 24 | $47.1M | $377.2M | ||
| Q3 24 | $138.7M | $476.1M | ||
| Q2 24 | $107.1M | $273.4M |
自由现金流EXASSWKS
| Q1 26 | — | $339.0M | ||
| Q4 25 | $120.4M | $144.0M | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $46.7M | $252.7M | ||
| Q1 25 | $-365.0K | $370.9M | ||
| Q4 24 | $10.7M | $338.2M | ||
| Q3 24 | $112.6M | $393.3M | ||
| Q2 24 | $71.2M | $249.0M |
自由现金流率EXASSWKS
| Q1 26 | — | 32.7% | ||
| Q4 25 | 13.7% | 13.1% | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 5.8% | 26.2% | ||
| Q1 25 | -0.1% | 38.9% | ||
| Q4 24 | 1.5% | 31.7% | ||
| Q3 24 | 15.9% | 38.4% | ||
| Q2 24 | 10.2% | 27.5% |
资本支出强度EXASSWKS
| Q1 26 | — | 5.5% | ||
| Q4 25 | 3.6% | 5.1% | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 5.2% | 6.4% | ||
| Q1 25 | 4.4% | 4.0% | ||
| Q4 24 | 5.1% | 3.6% | ||
| Q3 24 | 3.7% | 8.1% | ||
| Q2 24 | 5.1% | 2.7% |
现金转化率EXASSWKS
| Q1 26 | — | 4.99× | ||
| Q4 25 | — | 1.41× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 2.99× | ||
| Q1 25 | — | 5.96× | ||
| Q4 24 | — | 2.33× | ||
| Q3 24 | — | 7.87× | ||
| Q2 24 | — | 2.26× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
SWKS
| Sales Channel Through Intermediary | $915.6M | 88% |
| Sales Channel Directly To Consumer | $119.8M | 12% |
